Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
June 28, 2018 06:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience...
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
June 25, 2018 12:05 ET
|
Dynavax Technologies Corporation
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B Data Presented at 2018 American Diabetes Association...
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
June 11, 2018 06:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Michael Ostrach, Dynavax’s Chief Financial Officer, will present at the...
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2018 14:15 ET
|
Dynavax Technologies Corporation
Overall Response Rate (ORR) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of SD-101 Combination showed...
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
May 16, 2018 17:15 ET
|
Dynavax Technologies Corporation
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare...
Dynavax Reports First Quarter 2018 Financial Results
May 08, 2018 16:05 ET
|
Dynavax Technologies Corporation
Update on Initial Progress of HEPLISAV-B® Commercial Launch Conference Call to be Held at 4:30pm ET/1:30pm PT BERKELEY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation...
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 07, 2018 06:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the...
Dynavax to Host First Quarter 2018 Financial Results Conference Call
May 02, 2018 16:15 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018...
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
April 23, 2018 06:30 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention (CDC) published the Advisory...
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
April 17, 2018 09:07 ET
|
Dynavax Technologies Corporation
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR BERKELEY,...